ONCS News OncoSec OMS ElectroChemotherapy for Head

ONCS News OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies

2012-07-23 06:07 ET - News Release

Data Presented at the 8th International Conference on Head and Neck Cancer Demonstrate Equivalent Disease Control and Survival, and Improved Functional Outcomes and Quality of Life Compared to Surgery

SAN DIEGO, July 23, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck (SCCHN). The data are being presented July 22-24 at the 8th International Conference on Head and Neck Cancer in Toronto, Canada. A link to the abstract can be found here: http://ahns.jnabstracts.com/Detail.aspx?ID=0778

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO )

In these studies, electrochemotherapy was compared against surgery for quality of life, safety, survival and local control at eight months, where local control is defined as destruction of the treated tumor without evidence of reappearance of the tumor at the treatment site. The data show OMS ElectroChemotherapy achieved the primary endpoint of preserving quality of life compared to surgery, and appears to be safe and comparable to surgery in achieving control in locally recurrent or second primary SCCHN. This therapy represents a viable alternative to potentially major surgical interventions for this patient population, where recurrent tumors in SCCHN usually have a poor prognosis with a local control rate of 40-50 percent and frequently associated loss of organ function.